685111-88-0

Upstream product

• 777-52-6 1-dichlorophosphoryloxy-4-nitro-benzene 
• 685111-87-9 (-)-(S)-1-(pyridin-4-yl)-1,3-propanediol 
• 329325-42-0 (+)-(R)-1-(pyridin-4-yl)-1,3-propanediol 
• 100-02-7 4-nitro-phenol 
• 591228-11-4 3-hydroxy-3-(pyridin-4-yl)propionic acid ethyl ester 
• 1027138-30-2 ethyl 3-(L-2-N,N-dimethylamino-3-phenyl-propanoyloxy)-3-(pyridin-4-yl)-propanoate 
• 1026885-94-8 ethyl 3-(L-2-N,N-dimethylamino-3-phenyl-propanoyloxy)-3-(pyridin-4-yl)-propanoate 
• 872-85-5 pyridine-4-carbaldehyde 

Downstream Products

• 685111-92-6 (4S)-5'-O-cis-[4-(pyridin-4yl)-2-oxido-1,3,2-dioxaphosphorinan-2yl]-cytosine-β-D-arabinofuranoside 

Relevant academic research and scientific papers

Stereoselective synthesis of nucleoside monophosphate HepDirect prodrugs

Synthesis of HepDirect prodrugs of nucleoside monophosphates via phosphorylation with a chiral reagent forms a new asymmetric center at phosphorus and produces two diastereomers. Coupling of chiral phosphoramidite 6 derived from (S)-diol 5 with ara-A foll

Compound for treating metabolic diseases as well as preparation method and application thereof

The invention provides a compound for treating metabolic diseases, the compound has a structure represented by formula (I) or formula (II), or a racemate, a stereoisomer, a geometric isomer, a tautomer, a solvate, a hydrate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The compounds provided by the invention are FXR and/or TGR5 receptor activators, and the compounds havethe activity of activating FXR and/or TGR5 receptors, and can be used for preparing medicines for treating chronic liver diseases, metabolic diseases or portal hypertension.

Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-β-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma

Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. Th

Novel 2'-C-methyl nucleoside derivatives

Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:

Novel cytarabine monophosphate prodrugs

Compounds of Formula I, their preparation and uses are described: wherein: M and V are cis to one another and MH is cytarabine; the 5′ oxygen of said cytarabine is attached to the phosphorus; V is 4-pyridyl; and pharmaceutically acceptable prodrugs and salts thereof.

Design, Synthesis, and Characterization of a Series of Cytochrome P 450 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver

A new class of phosphate and phosphonate prodrugs, called HepDirect prodrugs, is described that combines properties of rapid liver cleavage with high plasma and tissue stability to achieve increased drug levels in the liver. The prodrugs are substituted c